Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Background: The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most common health care–associated IFI. We evaluated the activity of fluconazole (FLU) against 20 788 invasive isolates of Candida (37 species) collected from 135 medical centers in 39 countries (1997–2016). The activity of anidulafungin, caspofungin, and micafungin (MCF) was evaluated against 15 308 isolates worldwide (2006–2016). Methods: Species identification was accomplished using phenotypic (1997–2001), genotypic, and proteomic methods (2006–2016). All isolates were tested using reference methods and clinical breakpoints published in the Clinical and Laboratory Standards Institute documents. Results: A decrease in the isolation of Candida albicans and an increase in the isolation of Candida glabrata and Candida parapsilosis were observed over time. Candida glabrata was the most common non–C. albicans species detected in all geographic regions except for Latin America, where C. parapsilosis and Candida tropicalis were more common. Six Candida auris isolates were detected: 1 each in 2009, 2013, 2014, and 2015 and 2 in 2016; all were from nosocomial bloodstream infections and were FLU-resistant (R). The highest rates of FLU-R isolates were seen in C. glabrata from North America (NA; 10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%). A steady increase in isolation of C. glabrata and resistance to FLU was detected over 20 years in the United States. Echinocandin-R (EC-R) ranged from 3.5% for C. glabrata to 0.1% for C. albicans and C. parapsilosis. Resistance to MCF was highest among C. glabrata (2.8%) and C. tropicalis (1.3%) from NA. Mutations on FKS hot spot (HS) regions were detected among 70 EC-R isolates (51/70 were C. glabrata). Most isolates harboring FKS HS mutations were resistant to 2 or more ECs. Conclusions: EC-R and FLU-R remain uncommon among contemporary Candida isolates; however, a slow and steady emergence of resistance to both antifungal classes was observed in C. glabrata and C. tropicalis isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although relatively low levels of resistance for most Candida species have been described, the outcomes for candidemia remain poor, as high levels of mortality (15%-50%) have been associated with candida infections7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this Review, we explore the molecular mechanisms that contribute to antifungal drug resistance, with a focus on Candida spp., the most common cause of fungal infections in humans7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measured
22 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“Sentinel surveillance programs designed to capture organisms and patient demographic data from representative sites spanning a larger geographical area and over a longer period of time serve to fill the gaps in time and space that are necessarily left by the more intensive and focused, yet intermittent, population-bas…”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12]; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs.”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 2×
“S90 • OFID 2019:6 (Suppl 1) • Pfaller et al SENTRY Program Candida Surveillance (1997–2016) • OFID 2019:6 (Suppl 1) • S91 [93, 94], and emerging resistance mechanisms [20, 68] highlight the importance of local and global surveillance studies.”
BackgroundSelf-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Caspofungin, micafungin, and anidulafungin were approved for clinical use by the US Food and Drug Administration (FDA) in 2001, 2005, and 2006, respectively, and are now recommended as firstline agents for treating IC [50, 67].”
BackgroundCalderone, R. (2012) · ASM Press eBooks · Cited by 912
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citation
Research works printed but not linked: 4
- 38. CLSI. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- 39. CLSI. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
- 40. CLSI. M59. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- 63. Pfaller MA, Diekema DJ Azole antifungal drug cross-resistance: mechanisms epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1: 74– 92.
Cited by
Items 401–500 of 931
Deciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
Molecular characterization of fungal endophthalmitis and keratitis caused by yeasts
Belanger, N. L., Kim, S. J., & Bispo, P. J. M. (2022) · Medical Mycology · doi:10.1093/mmy/myac099 · Cited by 10
Jeenkeawpieam, J., Rodjan, P., Roytrakul, S., Pruksaphon, K., Mitsuwan, W., Tanthanathipchai, N., Boonkaewwan, C., Tedja, I., & Pongpom, M. (2023) · Veterinary World · doi:10.14202/vetworld.2023.1018-1028 · Cited by 10
Deng, R., Meng, X., Li, R., Wang, A., & Song, Y. (2023) · Medicine · doi:10.1097/md.0000000000033798 · Cited by 10
Leite, D. P. (2023) · Virology & Immunology Journal · doi:10.23880/vij-16000331 · Cited by 10
Bohner, F., Papp, C., Takács, T., Varga, M., Szekeres, A., Nosanchuk, J. D., Vágvölgyi, C., Tóth, R., & Gácser, A. (2023) · Journal of Fungi · doi:10.3390/jof9121148 · Cited by 10
Kovács, F., Balla, N., Bozó, A., Harmath, A., Jakab, Á., Tóth, Z., Nagy, F., Majoros, L., & Kovács, R. (2024) · Mycoses · doi:10.1111/myc.13727 · Cited by 10
Choudhary, D. K., Bhakt, P., & Kaur, R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00886-19 · Cited by 10
Antifungal Activity of Extracts, Fractions, and Constituents from Coccoloba cowellii Leaves
Méndez, D., Arranz, J. C. E., Pérez, E. M., Foubert, K., Matheeussen, A., Tuenter, E., Cuypers, A., Cos, P., & Pieters, L. A. C. (2021) · Pharmaceuticals · doi:10.3390/ph14090917 · Cited by 10
Madanchi, H., Rahmati, S., Doaei, Y., Sardari, S., Maleki, M. S. M., Rostamian, M., Kiasari, R. E., Mousavi, S. J. S., Ghods, E., & Ardekanian, M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105866 · Cited by 10
Thanyasrisung, P., Satitviboon, W., Howattanapanich, S., & Matangkasombut, O. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105628 · Cited by 10
Pfaller, M. A., Carvalhaes, C. G., Deshpande, L. M., Rhomberg, P. R., & Castanheira, M. (2023) · Journal of Fungi · doi:10.3390/jof9060608 · Cited by 10
Self-citationKim, E. J., Kwak, Y. G., Kwak, S. H., Ko, S. H., Kim, J. H., Kim, E. S., Kim, T. H., Ryu, S. Y., Moon, H., Park, S. H., et al. (2020) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2020.25.2.115 · Cited by 10
Fisetin-Mediated Perturbations of Membrane Permeability and Intracellular pH in Candida albicans
Kim, Y. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2311.11027 · Cited by 9
Nascimento, T., Inácio, J., Guerreiro, D., Diaz, P., Patrício, P., Proença, L., Toscano, C., & Barroso, H. (2024) · Infection Prevention in Practice · doi:10.1016/j.infpip.2024.100403 · Cited by 9
Clinical impact of fluconazole-resistant Candida parapsilosis : a narrative review
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2544443 · Cited by 9
Ahmed, F., El-Kholy, I. M. A., Abdou, D. A. M., El-Mehalawy, A. A., & Elkady, N. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-15302-3 · Cited by 9
Rihova, Z. J., Slobodova, L., & Hrabovská, A. (2021) · Journal of Fungi · doi:10.3390/jof7100800 · Cited by 9
Advancements in the pharmacological management of sepsis in the elderly
Psarrakis, C., & Giamarellos‐Bourboulis, E. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213828 · Cited by 9
Wang, X., Jin, X., Xie, Z., Zhang, H., Liu, T., Zheng, H., Luan, X., Sun, Y., Fang, W., Chang, W., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01068 · Cited by 9
Factors influencing outcomes in candidemia: A retrospective study of patients in a Swedish county
Klingspor, H. T., & Hällgren, A. (2024) · Mycoses · doi:10.1111/myc.13758 · Cited by 9
Pharmaceutical salts of azole anti-fungal drugs: physicochemical behaviour and activity studies
Qadri, H., Malik, A. A., Ahangar, A. A., Mir, M. A., Dar, A. A., & Shah, A. H. (2024) · RSC Pharmaceutics · doi:10.1039/d4pm00003j · Cited by 9
Said, A. M., Afridi, F. A., Redell, M. S., Vrana, C., O’Farrell, C., Scheurer, M. E., Garnes, N. D., Gramatges, M. M., & Dutta, A. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004502 · Cited by 9
Fang, X., Su, C., Luo, Y., Pan, K., Lin, J., You-liang, S., Huang, Y., Hu, X., & Shen, Z. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156803 · Cited by 9
Battu, A., Purushotham, R., Dey, P., Vamshi, S. S., & Kaur, R. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009355 · Cited by 9
Investigating Candida glabrata Urinary Tract Infections (UTIs) in Mice Using Bioluminescence Imaging
Schrevens, S., & Sanglard, D. (2021) · Journal of Fungi · doi:10.3390/jof7100844 · Cited by 9
Leepattarakit, T., Tulyaprawat, O., & Ngamskulrungroj, P. (2022) · Journal of Fungi · doi:10.3390/jof8100983 · Cited by 9
Arastehfar, A. A., Sadati, S. K., Zareshahrabadi, Z., Fang, W., Pan, W., Asadpour, E., Daneshnia, F., İlkit, M., Boekhout, T., Perlin, D. S., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myaa092 · Cited by 9
Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital
Alp, Ş., Gülmez, D., Kardaş, R. C., Karahan, G., Taş, Z., Gürsoy, G., Ayaz, Ç. M., Arıkan-Akdağlı, S., & Akova, M. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04147-5 · Cited by 9
Nickels, T. J., & Cunningham, K. W. (2025) · mSphere · doi:10.1128/msphere.00270-25 · Cited by 8
“(also known as Nakaseomyces glabratus ) is the second most common cause of candidia sis, its prevalence has been rising rapidly, possibly due to its innate resistance to azole-class antifungals and easily acquired resistance to echinocandin-class antifungals (7–9).”
Cugnata, S., Sacheli, R., Layios, N., & Hayette, M. (2025) · Journal of Fungi · doi:10.3390/jof11060465 · Cited by 8
Cuevas-Tello, J. C., la Rosa, A. M.-D., Quistian-Navarro, J. L., Martínez‐Gamboa, A., González-Lara, M. F., López-García, N. I., Rangel‐Cordero, A., López-Jácome, L. E., Cervantes-Hernández, M. I., Franco‐Cendejas, R., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf097 · Cited by 8
Overcoming Candida biofilm resistance: targeting persister cells with probiotic-derived metabolites
Debta, P., Sahu, B. K., Patra, S. K., Debta, F. M., Mishra, E., & Panda, S. K. (2026) · Frontiers in Antibiotics · doi:10.3389/frabi.2026.1767028 · Cited by 8
Tsybruk, T. V., Kaluzhskiy, L. A., Mezentsev, Y. V., Makarieva, T. N., Tabakmakher, K. M., Ivanchina, N. V., Dmitrenok, P. S., Baranovsky, A. V., Gilep, A. A., & Ivanov, A. S. (2023) · Biomedicines · doi:10.3390/biomedicines11112873 · Cited by 8
Empirical Therapy for Invasive Candidiasis in Critically Ill Patients
Bartalucci, C., Giacobbe, D. R., Vena, A., & Bassetti, M. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00489-1 · Cited by 8
Raj, K., Paul, D., Rishi, P., Shukla, G., Dhotre, D. P., & YogeshSouche (2024) · BMC Microbiology · doi:10.1186/s12866-024-03274-9 · Cited by 8
Effects of efflux pumps on antifungal activity of chitosan against Candida albicans
Muangsawat, S., Chaiyosang, P., Sinkanarak, P., Sukted, J., Thanyasrisung, P., & Matangkasombut, O. (2024) · Journal of Oral Microbiology · doi:10.1080/20002297.2024.2357976 · Cited by 8
Spectrum and management of rare Candida /yeast infections in Kuwait in the Middle East
Ahmad, S., Asadzadeh, M., Al‐Sweih, N., & Khan, Z. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241263733 · Cited by 8
The putative error prone polymerase REV1 mediates DNA damage and drug resistance in Candida albicans
Agyare-Tabbi, M. R., Uthayakumar, D., Francis, D., Maroc, L., Grant, C., McQueen, P., Westmacott, G., Shaker, H., Skulska, I., Gagnon‐Arsenault, I., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00057-0 · Cited by 8
Vajdič, T., & Erjavec, M. S. (2025) · Applied Microbiology · doi:10.3390/applmicrobiol5010030 · Cited by 8
Luo, Z., Ning, Y., Xiao, M., Guo, D., Xu, H., Liu, Y., Kang, M., Ji, X., Dai, R., Wang, H., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf156 · Cited by 8
Harrison, M., Rinker, D. C., LaBella, A. L., Opulente, D. A., Wolters, J. F., Zhou, X., Shen, X., Groenewald, M., Hittinger, C. T., & Rokas, A. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012091 · Cited by 8
Wright, W. F., Bejou, N., Shields, R. K., Marr, K. A., McCarty, T. P., & Pappas, P. G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-19 · Cited by 8
Species Distribution and Antifungal Susceptibilities of Candida Species Isolated From Blood Culture
Cılo, B. D. (2023) · Cureus · doi:10.7759/cureus.38183 · Cited by 8
Candida auris: A bibliometric analysis of an emerging global health threat
Ragusa, P., Prinzivalli, A., Pizzini, S., Libero, G., Moro, G. L., Brescia, V., Scaioli, G., Minniti, D., Siliquini, R., & Bert, F. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.012 · Cited by 8
Chow, E. W. L., Song, Y., Wang, H., Xu, X., Gao, J., & Wang, J. (2024) · Molecular Microbiology · doi:10.1111/mmi.15229 · Cited by 8
Emerging trends of invasive yeast infections and azole resistance in Beijing intensive care units
Yu, J., Yang, W., Fan, X., Cui, E., Min, R., Yuan, H., Hu, Y., Wang, H., Zhang, G., Zhao, Y. Y., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.04.020 · Cited by 8
Tan, X., Baugh, K., Bulman, Z. P., & Wenzler, E. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00388-1 · Cited by 8
Jin, Y., Wang, Z., Zhu, C., Yang, Q., Lu, Y., Yu, X., Hong, B., Wang, X., & Zhang, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.627166 · Cited by 8
Kim, E. J., Kwak, Y. G., Kwak, S. H., Ko, S. H., Kweon, O. M., Kim, E. S., Kim, J. H., Kim, T. H., Kim, T. S., Moon, H., et al. (2021) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2021.26.2.115 · Cited by 8
Edlind, T., & Katiyar, S. K. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00721-22 · Cited by 8
A pseudo-outbreak of Cyberlindnera fabianii funguria: Implication from whole genome sequencing assay
Fan, X., Dai, R., Kudinha, T., & Gu, L. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1130645 · Cited by 8
Karakoyun, A. S., Spruijtenburg, B., Ünal, N., Meijer, E. F. J., Sucu, M., Polat, S. H., Meis, J. F. G. M., de Groot, T., & İlkit, M. (2024) · Medical Mycology · doi:10.1093/mmy/myae005 · Cited by 8
Li, Y., Hou, X., Li, R., Liao, K., Ma, L., Wang, X., Ji, P., Kong, H., Xia, Y., Ding, H., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03105-3 · Cited by 7
“Among the tested echi-nocandins, micafungin showed significantly better in vitro activity against the C. glabrata isolates than both anidulafungin and caspofungin, which is consistent with the results of the SENTRY Antifungal Surveillance Program [21].”
BackgroundResultInfluentialLin, C.-J., Yang, S.-Y., Hsu, L.-H., Yu, S.-J., & Chen, Y.-L. (2023) · Medical Mycology · doi:10.1093/mmy/myad004 · Cited by 7
Pariano, M., Puccetti, M., Fabi, C., Nunzi, E., Balucchi, S., Perioli, L., Ricci, M., Giovagnoli, S., Garaci, E., & Romani, L. R. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2569831 · Cited by 7
Cao, Y., Li, Y., Wang, M., Wu, Y., Shi, S., Wang, C., Gao, Z., Yang, W., Wang, L., & Kang, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1658476 · Cited by 7
Logan, C., Allebone-Salt, P. E., Mazzella, A., Hemsley, C. J., Goodman, A. L., Ward, C., Fife, A., Schelenz, S., Abdolrasouli, A., & Bicanic, T. A. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106692 · Cited by 7
Ira-Bonouman, A., Krasteva, D., Kouadjo, F. K., Roger, F., Bellet, V., Koffi, D., Pottier, C., Touré, O. A., Drakulovski, P., Djaman, A. J., et al. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101410 · Cited by 7
Önal, P., Aygün, D., Apaydın, G., Eren, B. A., Kes, G., Aygün, F., Zübarioğlu, T., Beşer, Ö. F., Ocak, S., Yazgan, Z., et al. (2024) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmae015 · Cited by 7
Intra‐Abdominal Candidiasis in Cancer Patients: A 10‐Year Experience in a Middle‐Income Country
de Almeida, B. L., Arcieri, V. C., Razente, D. M., Freire, M. P., Guimarães, T., de Araújo, E. D. M. P. A., Abdala, E., & Magri, M. M. C. (2024) · Mycoses · doi:10.1111/myc.13807 · Cited by 7
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., Cabrera, N., İlkit, M., Desai, J. V., Gabaldón, T., Shor, E., & Perlin, D. S. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae035 · Cited by 7
Paul, R. A., Madduri, M., Kashyap, N., Ramesh, S., Rudramurthy, S. M., & Roy, U. (2024) · Apmis · doi:10.1111/apm.13506 · Cited by 7
Jain, K., Mishra, B., Tiwari, A., Siddiqui, S. I., Areeshi, M. Y., Haque, S., Chowdhary, A., & Kaur, H. (2025) · ChemistrySelect · doi:10.1002/slct.202404088 · Cited by 7
Jayaweera, S. L. D., Van, T. T. H., & Dias, D. A. (2025) · Journal of Xenobiotics · doi:10.3390/jox15010032 · Cited by 7
Castanheira, M., Deshpande, L. M., Kimbrough, J. H., & Winkler, M. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae702 · Cited by 7
Self-citationHeterogeneity of Candida bloodstream isolates in an academic medical center and affiliated hospitals
Scott, N. E., Wash, E., Zajac, C., Erayil, S. E., Kline, S. E., & Selmecki, A. M. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00464-25 · Cited by 7
Kayıran, S. D., TAVLI, Ö. F., Kara, E. M., Kaplan, A., Şahin, H., Boğa, M., & Özkan, E. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1618761 · Cited by 7
Candida Infections in Solid Organ Transplantation
Barros, N., & Mansour, M. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-25869-6_43 · Cited by 7
Xue, B., Yu, Y., Peng, G., Sun, M., Lv, P., & Li, X. (2022) · Molecules · doi:10.3390/molecules27103079 · Cited by 7
Satała, D., Karkowska‐Kuleta, J., Braś, G., Rąpała‐Kozik, M., & Kozik, A. (2023) · Yeast · doi:10.1002/yea.3847 · Cited by 7
Wang, M., Zhang, C., Li, Z., Ji, B., Man, S., Yi, M., Li, R., Hao, M., & Wang, S. (2023) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2023.100518 · Cited by 7
One Health Approach to Addressing Fungal Infection Disparities
Sengupta, M., Kundu, A., Nayak, G., Srivastava, S., & Banerjee, S. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00480-2 · Cited by 7
Environmental and Social Determinants Related to Candidiasis
Morales-Ramírez, K. D. C., Ávila-Sosa, R., Cid-Pérez, T. S., Avelino-Flores, F., Duarte-Escalante, E., & Munguía-Pérez, R. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004600 · Cited by 7
Glushakova, A. M., & Качалкин, А. В. (2024) · Birds · doi:10.3390/birds5030036 · Cited by 7
Candida and candidemia in Korea
Kwon, Y. J., & Shin, J. H. (2024) · Annals of Clinical Microbiology · doi:10.5145/acm.2024.27.4.3 · Cited by 7
Kumar, D., Chaudhary, M., Midha, N. K., Bohra, G. K., Meena, D. S., Tak, V., Rathore, H., Rathore, V., Vaishnavi, M., Neetha, T. R., et al. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241305043 · Cited by 7
The secreted acid trehalase encoded by the CgATH1 gene is involved in Candida glabrata virulence
Lopes, R. G., Muñoz, J. E., Barros, L. M., Júnior, S. L. A., Taborda, C. P., & Stambuk, B. U. (2020) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200401 · Cited by 7
Racial disparities among candidemic patients at a Southern California teaching hospital
Grant, V. C., Zhou, A. Y., Tan, K. K., & Abdul‐Mutakabbir, J. C. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.74 · Cited by 7
Asadzadeh, M., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1242622 · Cited by 7
Puumala, E., Sychantha, D., Lach, E., Reeves, S., Nabeela, S., Fogal, M., Nigam, A., Johnson, J. W., Aspuru‐Guzik, A., Shapiro, R. S., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.010 · Cited by 7
Sahu, M. S., Purushotham, R., & Kaur, R. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011281 · Cited by 7
Post-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“%) has been reported for Candida glabrata, Candida tropicalis, and Candida auris (Pfaller et al. 2019; Arastehfar et al. 2020; Chow et al. 2020; Nishimoto et al. 2020).”
BackgroundAsadzadeh, M., Alobaid, K., Ahmad, S., & Mazloum, S. (2023) · Journal of Fungi · doi:10.3390/jof9080784 · Cited by 6
Streptomyces: a natural source of anti-Candida agents
Martins, N. D. R. C., da Silva, A. R., Ratcliffe, N. A., Evangelho, V. G. O., Castro, H. C., & Quinn, G. A. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001777 · Cited by 6
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 6
Saeed, N. K., Almusawi, S., & Al‐Beltagi, M. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i4.98839 · Cited by 6
Benahmed, A., Seghir, A., Dergal, F., Chiali, A., Boucherit‐Otmani, Z., & Ziani‐Cherif, C. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107280 · Cited by 6
Chemoproteomic Profiling of C. albicans for Characterization of Antifungal Kinase Inhibitors
Shirley, D. J., Nandakumar, M., Cabrera, A., Yiu, B., Puumala, E., Liu, Z., Robbins, N., Whitesell, L. J., Smith, J. L., Lyons, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00097 · Cited by 6
Candida infections in COVID-19 patients: A review of prevalence, risk factors, and mortality
TÚLIO, E. F., Lucini, F., de Lima, A. C., Martins, N. D. G., Barbosa, M. D. S., de Souza, G. H. D. A., & Rossato, L. L. (2025) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2025.100831 · Cited by 6
Employing machine learning for identifying antifungal compounds against Candida albicans
de Souza, D. R., Silva, L. D. C., Silva, K. S. F. E., de Jesus, F. S., de Oliveira, A. A., Neves, B. J., & Pereira, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2525717 · Cited by 6
Benwan, K. A., Ahmed, S. A., Banwan, D. A., & John, M. (2025) · Journal of Fungi · doi:10.3390/jof11090670 · Cited by 6
Woods, M., McAlister, J. A., Segeren, L., da Silva, M. B., Deyarmin, J. S., Hakimi, A., Hermanson, D. J., Richter, J., Samra, S. N., & Geddes‐McAlister, J. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101083 · Cited by 6
Ferreira, P. A. A., Roso, L. D. C., Freitas, D. A., Bressani, A. P. P., Ferreira, P. H. D. C., Bodevan, E. C., Moura, C. R. F., Schwan, R. F., Mendonça, V. A., Magalhães‐Guedes, K. T., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010241 · Cited by 6
The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management
Bagga, R., & Sridhar, K. K. (2026) · Microorganisms · doi:10.3390/microorganisms14030599 · Cited by 6
Jain, K., Shukla, N., Kaur, A., Kalita, B., Srivastava, S., Yadav, S., Rani, P., Kagra, P., Singh, A. K., Chaudhary, K., et al. (2026) · mBio · doi:10.1128/mbio.00235-26 · Cited by 6
Emerging and Re-emerging Fungal Infections
Francesconi, F., Francesconi, V. A., Lupi, O., & Khalfe, Y. (2021) · Updates in clinical dermatology · doi:10.1007/978-3-030-68321-4_9 · Cited by 6
Druseikis, M. E., Mottola, A., & Berman, J. G. (2023) · Current Clinical Microbiology Reports · doi:10.1007/s40588-023-00189-3 · Cited by 6
Fungal Spectrum and Susceptibility Against Nine Antifungal Agents in 525 Deep Fungal Infected Cases
Cai, W., Ruan, Q., Li, J., Li, L., Xi, L., Sun, J., & Lu, S. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s403863 · Cited by 6
Hwang, I. J., Kwon, Y. J., Lim, H. J., Hong, K. H., Lee, H., Yong, D., Won, E. J., Byun, S. A., Lee, G. Y., Kim, S. H., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00883-24 · Cited by 6
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N.
- Affiliations
- University of Iowa (US)
- The University of Adelaide (AU)
- JMI Laboratories (US)
- Corresponding author
- Pfaller, Michael A
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03
- Volume
- 6
- Issue
- Supplement_1
- Pages
- S79-S94
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC6419901
- OpenAlex
- W2922388167
- Semantic Scholar
- b99f36f4463b9afe6d2a0ab52eebb3f5e726f4c0
- Cited by
- 825
- References
- 114
- Citations by year
- 2026: 92 · 2025: 129 · 2024: 133 · 2023: 141 · 2022: 94 · 2021: 108 · 2020: 104 · 2019: 24
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- JMI Laboratories
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- invasive candidiasis, Candida species, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida auris, micafungin resistance, caspofungin, anidulafungin, Candida species distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.